Literature DB >> 22471402

Interaction of cisplatin with human superoxide dismutase.

Lucia Banci1, Ivano Bertini, Olga Blaževitš, Vito Calderone, Francesca Cantini, Jiafei Mao, Angela Trapananti, Miguela Vieru, Ilaria Amori, Mauro Cozzolino, Maria Teresa Carrì.   

Abstract

cis-Diamminedichloroplatinum(II) (cisplatin) is able to interact with human superoxide dismutase (hSOD1) in the disulfide oxidized apo form with a dissociation constant of 37 ± 3 μM through binding cysteine 111 (Cys111) located at the edge of the subunit interface. It also binds to Cu(2)-Zn(2) and Zn(2)-Zn(2) forms of hSOD1. Cisplatin inhibits aggregation of demetalated oxidized hSOD1, and it is further able to dissolve and monomerize oxidized hSOD1 oligomers in vitro and in cell, thus indicating its potential as a leading compound for amyotrophic lateral sclerosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22471402     DOI: 10.1021/ja211591n

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  18 in total

1.  Crystallography and chemistry should always go together: a cautionary tale of protein complexes with cisplatin and carboplatin.

Authors:  Ivan Shabalin; Zbigniew Dauter; Mariusz Jaskolski; Wladek Minor; Alexander Wlodawer
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2015-08-28

2.  Medical history of chemotherapy or immunosuppressive drug treatment and risk of amyotrophic lateral sclerosis (ALS).

Authors:  Thomas Kuczmarski; Elijah W Stommel; Kristen Riley; Rup Tandan; Vinay Chaudhry; Lora Clawson; Tracie A Caller; Patricia L Henegan; Dominic N Facciponte; Walter G Bradley; Angeline S Andrew
Journal:  J Neurol       Date:  2017-07-15       Impact factor: 4.849

3.  Interaction of Half Oxa-/Half cis-Platin Complex with Human Superoxide Dismutase and Induced Reduction of Neurotoxicity.

Authors:  Francesca Cantini; Vito Calderone; Lorenzo Di Cesare Mannelli; Magdalena Korsak; Leonardo Gonnelli; Oscar Francesconi; Carla Ghelardini; Lucia Banci; Cristina Nativi
Journal:  ACS Med Chem Lett       Date:  2018-10-01       Impact factor: 4.345

4.  Symmetry-breaking transitions in the early steps of protein self-assembly.

Authors:  Carmelo La Rosa; Marcello Condorelli; Giuseppe Compagnini; Fabio Lolicato; Danilo Milardi; Trang Nhu Do; Mikko Karttunen; Martina Pannuzzo; Ayyalusamy Ramamoorthy; Franca Fraternali; Francesca Collu; Human Rezaei; Birgit Strodel; Antonio Raudino
Journal:  Eur Biophys J       Date:  2020-03-02       Impact factor: 1.733

5.  Toxic SOD1 trimers are off-pathway in the formation of amyloid-like fibrils in ALS.

Authors:  Brianna Hnath; Nikolay V Dokholyan
Journal:  Biophys J       Date:  2022-05-03       Impact factor: 3.699

6.  Screening of Drugs Inhibiting In vitro Oligomerization of Cu/Zn-Superoxide Dismutase with a Mutation Causing Amyotrophic Lateral Sclerosis.

Authors:  Itsuki Anzai; Keisuke Toichi; Eiichi Tokuda; Atsushi Mukaiyama; Shuji Akiyama; Yoshiaki Furukawa
Journal:  Front Mol Biosci       Date:  2016-08-09

Review 7.  Cysteine Modifications in the Pathogenesis of ALS.

Authors:  Cristiana Valle; Maria Teresa Carrì
Journal:  Front Mol Neurosci       Date:  2017-01-23       Impact factor: 5.639

8.  Ligand binding and aggregation of pathogenic SOD1.

Authors:  Gareth S A Wright; Svetlana V Antonyuk; Neil M Kershaw; Richard W Strange; S Samar Hasnain
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

9.  The binding characteristics of isoniazid with copper-zinc superoxide dismutase and its effect on enzymatic activity.

Authors:  Nana Du; Liangquan Sheng; Zhaodi Liu; Xiaojuan Hu; Huajie Xu; Shuisheng Chen
Journal:  Chem Cent J       Date:  2013-06-06       Impact factor: 4.215

10.  A faulty interaction between SOD1 and hCCS in neurodegenerative disease.

Authors:  Gareth S A Wright; Svetlana V Antonyuk; S Samar Hasnain
Journal:  Sci Rep       Date:  2016-06-10       Impact factor: 4.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.